Select year

2025 2024 2023 2022 2021 Earlier

shown/page

5

2024.11.18

Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price
Major NRDL Update｜Chipscreen’s Epidaza® Becomes the Only Oral Novel Drug for First-Line DLBCL, while Bilessglu® Retains Listing at Current Price

2024.10.17

Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets： Investigational New Drug (IND) Application Accepted

2024.10.15

Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting

2024.07.23

NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment
NMPA Approves Phase III Clinical Trial Application for Chipscreen’s Class I Innovative Anti-Tumor Drug Chidamide in Colorectal Cancer Treatment

2024.07.19

Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes
Chiglitazar Sodium (Bilessglu®) in Combination with Metformin Approved by NMPA for Type 2 Diabetes

Media contact

Media contact

（+86）0755-36993500
pr@chipscreen.com